[A case of primary progressive multiple sclerosis with improvement in cognitive impairment by anti-CD20 monoclonal antibody therapy]

Rinsho Shinkeigaku. 2023 Mar 29;63(3):152-158. doi: 10.5692/clinicalneurol.cn-001779. Epub 2023 Mar 25.
[Article in Japanese]

Abstract

The patient was a 44-year-old man who developed cognitive impairment beginning at the age of 35 years that gradually worsened. The cognitive impairment led to a difficult social life, and he retired from his company. After hospitalization and workup, he was diagnosed with primary progressive multiple sclerosis (PPMS) that presented only with cognitive impairment for 10 years. Since he had multiple predictive factors for poor prognosis, anti-CD20 monoclonal antibody therapy was implemented. Cognitive impairment and cerebral blood flow SPECT findings improved, and he returned to a social life 3 months later. Anti-CD20 monoclonal antibody therapy was effective in improving cognitive impairment in a case of an advanced stage of PPMS.

Keywords: anti-CD20 monoclonal antibody; cognitive impairment; poor prognosis predictors; primary progressive multiple sclerosis.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Adult
  • Antibodies, Monoclonal
  • Antineoplastic Agents* / therapeutic use
  • Cognitive Dysfunction* / drug therapy
  • Cognitive Dysfunction* / etiology
  • Humans
  • Male
  • Multiple Sclerosis* / drug therapy
  • Multiple Sclerosis, Chronic Progressive* / complications
  • Multiple Sclerosis, Chronic Progressive* / drug therapy
  • Multiple Sclerosis, Chronic Progressive* / psychology

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents